Cargando…

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

BACKGROUND: Three-dose regimens for human papillomavirus (HPV) vaccines are expensive and difficult to complete, especially in settings where the need for cervical cancer prevention is greatest. METHODS: We evaluated the vaccine efficacy of fewer than three doses of the HPV16/18 vaccine Cervarix in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kreimer, Aimée R., Rodriguez, Ana Cecilia, Hildesheim, Allan, Herrero, Rolando, Porras, Carolina, Schiffman, Mark, González, Paula, Solomon, Diane, Jiménez, Silvia, Schiller, John T., Lowy, Douglas R., Quint, Wim, Sherman, Mark E., Schussler, John, Wacholder, Sholom
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2011
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3186781/ https://www.ncbi.nlm.nih.gov/pubmed/21908768 http://dx.doi.org/10.1093/jnci/djr319

Ejemplares similares

Reduced Prevalence of Oral Human Papillomavirus (HPV) 4 Years after Bivalent HPV Vaccination in a Randomized Clinical Trial in Costa Rica
por: Herrero, Rolando, et al.
Publicado: (2013)

Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment
por: Hildesheim, Allan, et al.
Publicado: (2016)

Effect of bivalent human papillomavirus vaccination on pregnancy outcomes: long term observational follow-up in the Costa Rica HPV Vaccine Trial
por: Panagiotou, Orestis A, et al.
Publicado: (2015)

Evidence for single-dose protection by the bivalent HPV vaccine—Review of the Costa Rica HPV vaccine trial and future research studies
por: Kreimer, Aimée R., et al.
Publicado: (2018)

Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: pooled analysis of two randomised controlled trials
por: Wacholder, Sholom, et al.
Publicado: (2010)

Determinants of seropositivity among HPV-16/18 DNA positive young women
por: Porras, Carolina, et al.
Publicado: (2010)

Common Genetic Variants and Risk for HPV Persistence and Progression to Cervical Cancer
por: Wang, Sophia S., et al.
Publicado: (2010)

Single Nucleotide Polymorphisms in the PRDX3 and RPS19 and Risk of HPV Persistence and Cervical Precancer/Cancer
por: Safaeian, Mahboobeh, et al.
Publicado: (2012)

HPV16 infection decreases vaccine-induced HPV16 antibody avidity: the CVT trial
por: Tsang, Sabrina H., et al.
Publicado: (2022)

A prospective study of absolute risk and determinants of human papillomavirus incidence among young women in Costa Rica
por: Clarke, Megan, et al.
Publicado: (2013)

HPV16 Seropositivity and Subsequent HPV16 Infection Risk in a Naturally Infected Population: Comparison of Serological Assays
por: Lin, Shih-Wen, et al.
Publicado: (2013)

Analysis of cervical HPV infections among unvaccinated young adult women to inform vaccine strategies in this age group: the Costa Rica HPV Vaccine Trial
por: Sierra, Mónica S., et al.
Publicado: (2023)

Comparison of Antibody Responses to Human Papillomavirus Vaccination as Measured by Three Assays
por: Robbins, Hilary A., et al.
Publicado: (2014)

A large, population-based study of age-related associations between vaginal pH and human papillomavirus infection
por: Clarke, Megan A, et al.
Publicado: (2012)

Glutathione S-transferase L1 multiplex serology as a measure of cumulative infection with human papillomavirus
por: Robbins, Hilary A, et al.
Publicado: (2014)

Sequence Imputation of HPV16 Genomes for Genetic Association Studies
por: Smith, Benjamin, et al.
Publicado: (2011)

Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study
por: Castle, Philip E, et al.
Publicado: (2009)

Comparing one dose of HPV vaccine in girls aged 9–14 years in Tanzania (DoRIS) with one dose of HPV vaccine in historical cohorts: an immunobridging analysis of a randomised controlled trial
por: Baisley, Kathy, et al.
Publicado: (2022)

Evaluation of TypeSeq, a Novel High-Throughput, Low-Cost, Next-Generation Sequencing-Based Assay for Detection of 51 Human Papillomavirus Genotypes
por: Wagner, Sarah, et al.
Publicado: (2019)

Explanations for the high potency of HPV prophylactic vaccines
por: Schiller, John, et al.
Publicado: (2018)

Cervicovaginal microbiome and natural history of HPV in a longitudinal study
por: Usyk, Mykhaylo, et al.
Publicado: (2020)

HPV co-factors related to the development of cervical cancer: results from a population-based study in Costa Rica
por: Hildesheim, A, et al.
Publicado: (2001)

Evolution and Taxonomic Classification of Alphapapillomavirus 7 Complete Genomes: HPV18, HPV39, HPV45, HPV59, HPV68 and HPV70
por: Chen, Zigui, et al.
Publicado: (2013)

Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67
por: Chen, Zigui, et al.
Publicado: (2011)

HPV16 E6 seropositivity among cancer-free men with oral, anal or genital HPV16 infection
por: Beachler, Daniel C., et al.
Publicado: (2016)

T cell receptor repertoire among women who cleared and failed to clear cervical human papillomavirus infection: An exploratory proof-of-principle study
por: Lang Kuhs, Krystle A., et al.
Publicado: (2018)

Deep sequencing of HPV16 genomes: A new high-throughput tool for exploring the carcinogenicity and natural history of HPV16 infection
por: Cullen, Michael, et al.
Publicado: (2015)

A population-based cross-sectional study of age-specific risk factors for high risk human papillomavirus prevalence in rural Nigeria
por: Clarke, Megan A, et al.
Publicado: (2011)

Next Generation Cancer Protection: The Bivalent HPV Vaccine for Females
por: Harper, Diane M., et al.
Publicado: (2011)

Detection of HPV DNA in paraffin-embedded cervical samples: a comparison of four genotyping methods
por: Castro, Felipe A., et al.
Publicado: (2015)

Predictors of the Therapeutic Response to Intralesional Bivalent HPV Vaccine in Wart Immunotherapy
por: Hammad, Noha M., et al.
Publicado: (2021)

Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa
por: Michaeli, Daniel Tobias, et al.
Publicado: (2022)

Involvement of nucleophosmin (NPM1/B23) in assembly of infectious HPV16 capsids
por: Day, Patricia M., et al.
Publicado: (2015)

False positive cervical HPV screening test results
por: Schiffman, Mark, et al.
Publicado: (2019)

Issues in optimising and standardising the accuracy and utility of the colposcopic examination in the HPV era
por: Schiffman, Mark, et al.
Publicado: (2015)

REPRODUCIBLE AND CLINICALLY TRANSLATABLE DEEP NEURAL NETWORKS FOR CANCER SCREENING
por: Ahmed, Syed Rakin, et al.
Publicado: (2023)

HPV vaccination initiation after the routine-recommended ages of 11–12 in the United States
por: Beachler, Daniel C., et al.
Publicado: (2015)

Direct, indirect and total effectiveness of bivalent HPV vaccine in women in Galicia, Spain
por: Purriños-Hermida, M. Jesus, et al.
Publicado: (2018)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Mood After CPAP: Fewer Patients With Depression, but not Fewer With Anxiety
por: Marrone, Oreste
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ah4dvnn449h8fr8r83i0jf57v7